Furthermore, CC patients with both high tumor mutation burden (TMB) and BRAF mutation always present a high level of immune infiltration with an abundant expression of immune checkpoint molecules such as PD-L1 (14), and BRAF is a biomarker for immunotherapy in melanoma (15). This evidence concerns the gene BRAF and neoplasm.